BFM
LYEL icon

Boothbay Fund Management’s Lyell Immunopharma LYEL Stock Holding History

Boothbay Fund Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,516
Closed -$293K – 2304
2025
Q4 		$293K Sell
9,516
-2,718
-22% -$60.8K ﹤0.01% 1450
2025
Q3 		$199K Hold
12,234
– – ﹤0.01% 1646
2025
Q2 		$108K Sell
12,234
-2
-0% -$18 ﹤0.01% 1307
2025
Q1 		$132K Sell
12,236
-8,076
-40% -$98.9K ﹤0.01% 1210
2024
Q4 		$260K Buy
20,312
+13,318
+190% +$264K 0.01% 1119
2024
Q3 		$193K Hold
6,994
– – ﹤0.01% 1403
2024
Q2 		$203K Buy
+6,994
New +$333K ﹤0.01% 1287

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boothbay Fund Management's LYEL Position: Q1 2026 in Review

Boothbay Fund Management sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 9,516 shares — an estimated $293K sold.

Boothbay Fund Management first reported a position in LYEL in Q2 2024 and held it in 7 quarters. The position peaked at $293K in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Boothbay Fund Management reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 9,516 Lyell Immunopharma shares in Q1 2026, an estimated $293K.
  • Boothbay Fund Management first reported a position in Lyell Immunopharma in Q2 2024 and held it in 7 quarters.
  • Boothbay Fund Management's Lyell Immunopharma position peaked at $293K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.